The recent unfortunate experience of chest wall recurrence of lung cancer at the site of previous fine needle aspiration biopsy seven months following resection of a T1N0M0 tumor has prompted us to reconsider the indications for this procedure. Transthoracic fine needle aspiration of lung tumors is a well-established and often useful diagnostic technique. In addition [...]
Almost all of the roentgenographically occult, sputum cytology positive lung cancers are squamous cell carcinomas. Detection and localization of these occult lung cancers have long presented a diagnostic challenge. Even for experienced endoscopists, carcinoma in situ is bronchoscopically visible in less than 30 percent of cases and microinvasive tumors are visible in only about two [...]
The findings on white light bronchoscopic exami-nation and fluorescence imaging are shown in Table I. Subtle mucosal changes were observed at five of the ten tumor sites. Positive fluorescence was observed in all ten sites. Elevated red-green ratios in the tumor area vs the control area were also observed at all ten sites. In areas [...]
BMents Four patients with roentgenographically occult carcinoma in situ were studied. Patient 1, a 59-year-old smoker with severe chronic obstructive lung disease, presented with hemoptysis. Chest x-ray film and CT scan did not show any endobronchial abnormality. Sputum cytology showed squamous carcinoma cells. Bronchoscopy at another hospital failed to localize the source of the cancer [...]
Lung cancer is the most common cause of cancer death in North America. The overall five-year survival of patients with lung cancer ranges from 10 to 13 percent. In patients with early lung cancer (TIS NO MO and T1 NO MO), the five-year survival is over 90 percent after surgical resection. Fluorescence bronchoscopy following administration [...]
Speaker: Deborah Hurst, MD, Senior Director of Clinical Development, Chiron Corporation, Emeryville, California. Low-dose interleukin-2 (IL-2) (Proleukin, Chiron), when administered in combination with rituximab (Rituxan, Genen-tech/IDEC) produces positive clinical responses in patients with advanced non-Hodgkin’s lymphoma (NHL), augmenting the antitumor activity of rituximab via expansion and activation of natural killer (NK) cells.
Speaker: Brian I. Carr, MD, Professor of Medicine, Director of the Liver Tumor Service, and Head of the Starzl Transplant Institute, University of Pittsburgh, Pittsburgh, Pennsylvania. Glass beads that release highly targeted p-rays from 90yttrium (Therasphere, MDS Nordion) represent an effective and relatively non-toxic treatment option for patients with unresectable and untransplantable advanced-stage hepatocel-lular carcinoma [...]
© 2008 HIV/AIDS News & Information